Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Efrat Lelkes, MD, Angira Patel, MD, MPH, Anna Joong, MD, and Jeffrey G. Gossett, MD
Current policy requires separate informed consent for some Public Health Service increased-risk donors, and this can make shared decision making harder.
AMA J Ethics. 2020;22(5):E401-407. doi:
10.1001/amajethics.2020.401.
Dr Jing Li joins Ethics Talk to discuss her article, coauthored with Dr Robert Tyler Braun, Sophia Kakarala, and Dr Holly G. Prigerson: “How Should Cost-Informed Goals of Care Decisions Be Facilitated at Life’s End?”
Dr Mustfa K. Manzur joins Ethics Talk to discuss his article, coauthored with Drs Sharon Griswold and Wendy Dean: "What Should Clinicians Do When Health Services Are Improperly Billed in Their Names?"
Dr Christopher Whaley joins Ethics Talk to discuss his article, coauthored with Dr Austin Frakt: “If Patients Don’t Use Available Health Service Pricing Information, Is Transparency Still Important?”
Dr Kevin Schulman joins Ethics Talk to discuss his article, coauthored with Dr Barak Richman: “Informed Consent as a Means of Acknowledging and Avoiding Financial Toxicity as Iatrogenic Harm.”